Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8305883 | 1.00 | PRMT3 (0.46) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL5024036 | 0.97 | PRMT3 (0.43) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL15120484 | 0.91 | PRMT3 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Trolamine SCHEMBL4857518 | 0.89 | PRMT3 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL15427694 | 0.89 | PRMT3 (0.54) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL17486783 | 0.89 | PRMT3 (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL12969841 | 0.89 | PRMT3 (0.37) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL3319764 | 0.87 | CYP1A2 (0.47) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL23223465 | 0.87 | EPHX1 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL903463 | 0.87 | EPHX1 (0.39) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0876161-B1 | CONTRAST MEDIA | NYCOMED SALUTAR INC (US) | 2001-11-21 | — | — | EP | claimed |
| EP-4328309-A2 | LIPID COMPOSITION | FUJIFILM Corporation (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3981435-B1 | LIPID COMPOSITION | FUJIFILM CORP (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023141426-A1 | ALKANOLAMINE-CONTAINING MEMBRANES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-07-27 | — | — | WO | disclosed |
| US-9891523-B2 | Photosensitive dry film and process for producing printed wiring board using the same | TAIYO INK MFG. CO., LTD. (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20150382473-A1 | PHOTOSENSITIVE DRY FILM AND PROCESS FOR PRODUCING PRINTED WIRING BOARD USING THE SAME | TAIYO INK MANUFACTURING CO., LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2670764-B1 | C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8575094-B2 | Use of type-B lantibiotic-based compounds having antimicrobial activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | NOVACTA BIOSYSTEMS LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
| EP-0876161-B1 | CONTRAST MEDIA | NYCOMED SALUTAR INC (US) | 2001-11-21 | — | — | EP | disclosed |
| US-5491263-A | DECYCLIZATION OF AN OXAZOLIDINONE WITH A SECONDARY AMINE OR A SECONDARY ALKANOLAMINE | THE DOW CHEMICAL COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | PRMT3 122/4885CARM1 388/4885PRMT6 1279/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | PRMT3 4308/4885CARM1 4486/4885PRMT6 4274/4885 |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | PRMT3 3548/4885CARM1 3631/4885PRMT6 3611/4885 |
| US-20100016319-A1 | ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF | UROD, UTS2R, SLC14A1 | PRMT3 378/4885CARM1 520/4885PRMT6 660/4885 |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | PRMT3 478/4885CARM1 1123/4885PRMT6 1117/4885 |
| US-20090203583-A1 | Use of Type-B Lantibiotic-Based Compounds having Antimicrobial Activity | MTPN, NISCH, VIP | PRMT3 4184/4885CARM1 4884/4885PRMT6 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.